ReviewFrontiers in immunology2021
Epstein-Barr Virus Epithelial Cancers-A Comprehensive Understanding to Drive Novel Therapies.
Review in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.
- Global Epidemiology of PD-L1 Expression in Epstein-Barr Virus-Associated Gastric Cancer: A Systematic Review and Meta-Analysis.Journal of gastrointestinal cancer · 2025Pooled it
- Functional contribution of Epstein-Barr virus BARF1 residues 35-39 to viable cell maintenance under serum deprivation and tumor formation.Virus genes · 2026Article
- T cell fate regulation in EBV‑associated nasopharyngeal carcinoma (Review).Oncology reports · 2026Review
- Core regulatory mechanisms of the PD-L1 axis and clinical strategies for immune escape and immunotherapy response in nasopharyngeal carcinoma.Translational oncology · 2026Review
- A System-Level Perspective on Epstein-Barr Virus Persistence: The Partial Lytic Reactivation.International journal of molecular sciences · 2026Review
- Epstein-Barr Virus Infection Is Associated with an Elevated Tumor-Stroma Ratio and Older Age in Oral Squamous Cell Carcinoma.Viruses · 2026Article
- Comprehensive management of advanced lymphoepithelioma-like hepatocellular carcinoma with immune-related colitis: a case report and literature review.Frontiers in oncology · 2026Article
- Epigenetics: the master switch of nasopharyngeal carcinoma invasion and metastasis.Frontiers in immunology · 2026Review
- Epstein-Barr virus-associated tumors: commonalities in pathogenesis and the tumor immune microenvironment.Frontiers in immunology · 2026Review
- Synergistic carcinogenesis of the nasopharyngeal microbiome and Epstein-Barr virus: mechanisms of metabolic reprogramming and immune evasion.Frontiers in immunology · 2026Review
- From Viral Infection to Malignancy: The Dual Threat of EBV and COVID-19 in Cancer Development.Viruses · 2025Review
- A Novel Polymersome Nanocarrier Promotes Anti-Tumour Immunity by Improved Priming of CD8Immunology · 2025Article
- Hip metastasis presenting as anterior knee pain from nasopharyngeal carcinoma: A case report.Oncology letters · 2025Article
- SITC strategic vision: prevention, premalignant immunity, host and environmental factors.Journal for immunotherapy of cancer · 2025Review
- A Case Report of Primary Pulmonary Lymphoepithelioma-Like Carcinoma with "Harmful" Pseudoprogression and a Pathological Complete Response (pCR) after Immunotherapy Plus Radiotherapy.Oncology research · 2025Article
- A Novel Inflammation-Marker-Based Prognostic Model for Advanced Pulmonary Lymphoepithelioma-Like Carcinoma.Journal of inflammation research · 2025Article
- Prediction of viral oncoproteins through the combination of generative adversarial networks and machine learning techniques.Scientific reports · 2024Article
- The Treatment of Primary Lymphoepithelioma-Like Carcinoma in the Head and Neck and Nasopharyngeal Carcinoma.Cancer medicine · 2024Review
- Mucosal T-cell responses to chronic viral infections: Implications for vaccine design.Cellular & molecular immunology · 2024Review
- Gammaherpesvirus Infection Stimulates Lung Tumor-Promoting Inflammation.Pathogens (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epstein-Barr virus (EBV) is a ubiquitous oncovirus associated with specific epithelial and lymphoid cancers. Among the epithelial cancers, nasopharyngeal carcinoma (NPC), lymphoepithelioma-like carcinoma (LELC), and EBV-associated gastric cancers (EBVaGC) are the most common. The role of EBV in the pathogenesis of NPC and in the modulation of its tumour immune microenvironment (TIME) has been increasingly well described. Much less is known about the pathogenesis and tumour-microenvironment interactions in other EBV-associated epithelial cancers. Despite the expression of EBV-related viral oncoproteins and a generally immune-inflamed cancer subtype, EBV-associated epithelial cancers have limited systemic therapeutic options beyond conventional chemotherapy. Immune checkpoint inhibitors are effective only in a minority of these patients and even less efficacious with molecular targeting drugs. Here, we examine the key similarities and differences of NPC, LELC, and EBVaGC and comprehensively describe the clinical, pathological, and molecular characteristics of these cancers. A deeper comparative understanding of these EBV-driven cancers can potentially uncover targets in the tumour, TIME, and stroma, which may guide future drug development and cast light on resistance to immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.